Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Brain Cancer Compound Demonstrates Potential

By R&D Editors | May 4, 2009

AngioChem, a Canadian-based biotechnology company, presented new clinical data at the American Association for Cancer Research (AACR) on a novel drug for brain cancers, ANG1005. The data, from two separate Phase 1/2 studies in  brain cancer patients, demonstrated that ANG1005 has potential efficacy in treating brain cancers as evidenced by tumor regression and the halting of tumor progression; has a favorable safety and tolerability profile; and has the ability to cross the blood-brain barrier to effectively deliver active therapeutic concentrations.

Treatment options for brain cancer patients are limited and prognoses are dismal due to the effective role the blood-brain barrier (BBB) serves as the natural guardian of the brain, preventing more than 95 percent of drugs from reaching the brain.

AngioChem is developing ANG1005 as its first clinical compound within a deep and broad pipeline of product candidates uniquely capable of crossing the BBB to treat a wide range of brain diseases.

“We are very excited by the encouraging tumor responses ANG1005 has produced in a trial that was designed primarily to assess safety and tolerability,” said Jean-Paul Castaigne, MD, president and chief executive officer of Angiochem. “We look forward to receiving the final data and, with the right partner, initiating a larger and possibly pivotal clinical trial early next year to further explore the potential of ANG1005.” 

AngioChem presented preliminary data from these two studies based on available data from 32 patients with malignant glioma and 42 patients with advanced solid tumor and brain metastases; enrollment in these studies continues. Key findings from the data from these patients, presented at AACR, include:

Tumor response data, as measured by magnetic resonance imaging (MRI) or computerized tomography (CT), show that ANG1005 has potential efficacy as evidenced by tumor regression and the halting of tumor progression;

Safety and tolerability data show that adverse events from treatment with ANG1005 were manageable and included neutropenia, leucopenia, thrombocytopenia and anemia;

Immunogenicity data, as measured by Enzyme-Linked ImmunoSorbent Assays (ELISA), show that ANG1005 does not elicit an immune response, including in patients who have received up to six treatment cycles;

Neurocognitive data show that ANG1005 does not show evidence of central nervous system toxicity.

Release date: April 21, 2009
Source: AngioChem 

 

Related Articles Read More >

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
Waters touts six-fold robustness with new Xevo TQ Absolute XR
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE